Skip Navigation


NDT Advance Access originally published online on May 11, 2007
Nephrology Dialysis Transplantation 2007 22(8):2224-2229; doi:10.1093/ndt/gfl747
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/8/2224    most recent
gfl747v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Boehme, M.
Right arrow Articles by Schindler, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boehme, M.
Right arrow Articles by Schindler, R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease

Michael Boehme1, Fenja Kaehne1, Anna Kuehne1, Wanja Bernhardt1, Matthias Schröder2, Wolfgang Pommer2, Christoph Fischer2, Helmut Becker2, Christian Müller1 and Ralf Schindler1

1Department of Nephrology and Medical Intensive Care Medicine, Charité – Universitaetsmedizin Berlin, Campus Virchow-Klinikum and 2KfH Dialysis Clinics Nordgraben/Bismarckstr., Berlin

Correspondence and offprint requests to: Ralf Schindler, MD, Department of Nephrology and Intensive Care Medicine, Charité, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin. Email: ralf.schindler{at}charite.de



  Abstract

Background. Pentraxins are mediators of inflammation as well as markers of the acute-phase reaction. While elevation of C-reactive protein (CRP) in patients with renal failure and its association with cardiovascular disease is well described, there are no data on pentraxin 3 (PTX3) in this population.

Methods. Plasma was obtained from 44 chronic haemodialysis (HD) patients, 35 peritoneal dialysis (PD) patients, 39 patients with chronic renal failure (CRF) not on dialysis therapy and 14 age-matched normal subjects. PTX3 production in whole blood was also investigated in samples taken before and during HD.

Results. PTX3 plasma levels were significantly higher in HD patients (5.8 ± 0.6 ng/ml) compared with the other three groups. There were no significant differences between PD patients (1.5 ± 0.4 ng/ml), CRF patients (1.5 ± 0.4 ng/ml) and normal subjects (0.76 ± 0.2 ng/ml). In dialysis patients, PTX3 levels correlated significantly with time on renal replacement therapy (RRT) and with weekly erythropoietin dose. PTX3 levels were significantly higher in patients with coronary artery disease and peripheral artery disease compared with those without. During a single HD session, PTX3 production was higher in whole blood samples taken after 3 h HD compared with samples taken before HD.

Conclusions. PTX3 levels are markedly elevated in HD patients. The increase in PTX3 production in whole blood after HD indicates that the HD procedure itself contributes to elevated PTX3 levels in HD patients. The association between PTX3 and cardiovascular morbidity suggests a possible connection of PTX3 with atherosclerosis and cardiovascular disease in HD patients.

Keywords: cardiovascular disease; chronic renal failure; C-reactive protein; haemodialysis; pentraxin

Received for publication: 13.10.06
Accepted in revised form: 8.11.06


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
P. Kunes, J. Mandak, M. Kolackova, and J. Krejsek
Mystery of pentraxin-3 not yet resolved: still a long way to its prime time in surgery
Nephrol. Dial. Transplant., March 1, 2009; 24(3): 1064 - 1065.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Boehme and R. Schindler
Reply
Nephrol. Dial. Transplant., March 1, 2009; 24(3): 1065 - 1066.
[Full Text] [PDF]


Home page
CJASNHome page
M. E. Suliman, M. I. Yilmaz, J. J. Carrero, A. R. Qureshi, M. Saglam, O. M. Ipcioglu, M. Yenicesu, M. Tong, O. Heimburger, P. Barany, et al.
Novel Links between the Long Pentraxin 3, Endothelial Dysfunction, and Albuminuria in Early and Advanced Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 976 - 985.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
M.E. Suliman, A.R. Qureshi, J.J. Carrero, P. Barany, M.I. Yilmaz, S. Snaedal-Jonsdottir, A. Alvestrand, O. Heimburger, B. Lindholm, and P. Stenvinkel
The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality
QJM, May 1, 2008; 101(5): 397 - 405.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
P. Stenvinkel, J. J. Carrero, J. Axelsson, B. Lindholm, O. Heimburger, and Z. Massy
Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle?
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 505 - 521.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.